tbuckley/cabot-search huggingface dataset:
In-Hospital Cardiopulmonary Resuscitation
Authors: Martin L. Evers
Journal: JAMA (1989)

To the Editor.—  The article In-Hospital Cardiopulmonary Resuscitation by Taffet et al 1 in the October 14 issue of JAMA addresses the problem of cardiopulmonary resuscitation (CPR) in the Houston (Tex) Veterans Administration Medical Center. They report an in-hospital mortality after CPR of 71.4% for all patients older than age 70 years (55/77 CPR efforts) at 24 hours, with none discharged alive. They further report that for those patients younger than age 70 years, 61.5% (198/322) were dead within 24 hours and that 8.4% of all patients who received CPR were discharged alive.  This article prompted us at Raritan Bay Medical Center, Perth Amboy, NJ, to review our data in reference to CPR. For the 9 months of January through September 1988 we had a total of 247 patients who received CPR, with a total of 279 CPR efforts. Our population included males and females. The results of our computerized
Abstract 16363: The Association Between Cerebral Oxygenation and Brain Waves Measured by Cerebral Oximetry and Electroencephalography (EEG) During Cardiopulmonary Resuscitation (CPR): A Feasibility Study
Authors: Elizabeth M Reagan, Robert T Nguyen, Shreyas Ravishankar, Vikram Chabra, Barbara Fuentes, Rebecca Spiegel, Sam Parnia
Journal: Circulation (2015)

Background: Cerebral ischemia following cardiac arrest (CA) is associated with significant morbidity and mortality. A major hurdle to improving CA outcomes has been the lack of a real-time detection system capable of identifying cerebral ischemia/oxygenation as well as brain function during CPR as markers of global ischemia. In particular no studies have examined the feasibility of real-time EEG and cerebral oximetry monitoring during CPR to evaluate for these parameters. Methods: This was a single center study using a convenience sample of CA patients enrolled between 03/2014 and 03/2015. Inclusion criteria: In/out of hospital CA, age ≥ 18 years. Portable EEG (Masimo) and cerebral oximetry (Nonin) were used during CPR cases lasting &gt;10 minutes. Raw EEG data were captured as consecutive images (1/second) during each pause in CPR (10 seconds), while oximetry was captured continuously. Results: 16 patients were recruited; mean age = 70±13 years; 11 males and 5 females. All subjects exhibited interpretable EEG patterns, while 50% (n=8/16) had &gt;1 interpretable pattern. There were 428 EEG images. 40.7% (n=174/428) were artifactual due to electrical interference, poor electrode adhesion or movement. 59.3% (n=254/428) were interpretable with seven distinct patterns identified: marked voltage attenuation (MVA) (78%), theta (8%), delta (5%), diffuse quasi-periodic discharge (4%), burst suppression (2%), spike/wave (2%), generalized rhythmic delta activity (1%). Based on known neurological associations, these patterns were further categorized as a) favorable (theta/delta) or b) unfavorable (the remaining patterns). No significant association was observed between cerebral oxygenation (rSO2) and favorable vs. unfavorable EEG patterns (median rSO2 (IQR) = 43.8% (39-48%) vs. 47.5% (42-52%) respectively). Conclusions: Real-time monitoring of cerebral oxygenation and function during CA is feasible. While MVA is the commonest EEG pattern, other distinct patterns also exist. Further studies are needed to explore the association between cerebral oxygenation and EEG patterns during CA as well as to identify intra-CA EEG and oximetry thresholds as markers for therapeutic interventions aimed at ameliorating cerebral ischemia during CA in real-time.
High Content Screening Identifies Synthetic Lethality Of Retinoid Receptor Agonists In IKZF1-Mutated BCR-ABL1 positive Acute Lymphoblastic Leukemia
Authors: Michelle Churchman, Jonathan Low, Debbie Payne-Turner, Shann-Ching Chen, Jing Ma, Mark J. Althoff, Faiyaz Notta, John E. Dick, Laura Janke, Rodney Kiplin Guy, Taosheng Chen, Charles G. Mullighan
Journal: Blood (2013)
Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling
Authors: Shingo Takada, Yoshihiro Masaki, Shintaro Kinugawa, Junichi Matsumoto, Takaaki Furihata, Wataru Mizushima, Tomoyasu Kadoguchi, Arata Fukushima, Tsuneaki Homma, Masashige Takahashi, Shinichi Harashima, Shouji Matsushima, Takashi Yokota, Shinya Tanaka, Koichi Okita, Hiroyuki Tsutsui
Journal: Cardiovascular Research (2016)

Exercise capacity is reduced in heart failure (HF) patients, due mostly to skeletal muscle abnormalities including impaired energy metabolism, mitochondrial dysfunction, fibre type transition, and atrophy. Glucagon-like peptide-1 (GLP-1) has been shown to improve exercise capacity in HF patients. We investigated the effects of the administration of a dipeptidyl peptidase (DPP)-4 inhibitor on the exercise capacity and skeletal muscle abnormalities in an HF mouse model after myocardial infarction (MI).MI was created in male C57BL/6J mice by ligating the left coronary artery, and a sham operation was performed in other mice. The mice were then divided into two groups according to the treatment with or without a DPP-4 inhibitor, MK-0626 [1 mg/kg body weight (BW)/day] provided in the diet. Four weeks later, the exercise capacity evaluated by treadmill test was revealed to be limited in the MI mice, and it was ameliorated in the MI + MK-0626 group without affecting the infarct size or cardiac function. The citrate synthase activity, mitochondrial oxidative phosphorylation capacity, supercomplex formation, and their quantity were reduced in the skeletal muscle from the MI mice, and these decreases were normalized in the MI + MK-0626 group, in association with the improvement of mitochondrial biogenesis. Immunohistochemical staining also revealed that a shift toward the fast-twitch fibre type in the MI mice was also reversed by MK-0626. Favourable effects of MK-0626 were significantly inhibited by treatment of GLP-1 antagonist, Exendin-(9-39) (150 pmol/kg BW/min, subcutaneous osmotic pumps) in MI + MK-0626 mice. Similarly, exercise capacity and mitochondrial function were significantly improved by treatment of GLP-1 agonist, Exendin-4 (1 nmol/kg/BW/h, subcutaneous osmotic pumps).A DPP-4 inhibitor may be a novel therapeutic agent against the exercise intolerance seen in HF patients by improving the mitochondrial biogenesis in their skeletal muscle.
Adaptation of Marrow Osteoblast Morphology Mediated By a Hematopoietic-Derived Endosteal Cell Is Critical for Donor HSC Engraftment after BMT
Authors: Kathleen Overholt, Satoru Otsuru, Victoria Best, Adam Guess, Timothy S. Olson, Massimo Dominici, Edwin M. Horwitz
Journal: Blood (2015)
Bortezomib Therapy for Multiple Myeloma in Relapse after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation (RICT).
Authors: Sophie Ducastelle, Daniela Revesz, Jacques Troncy, Samira Mahmoudi, Xavier Thomas, Anne Thiebaut, Franck E. Nicolini, Emmanuelle Tavernier, Quoc-Hung Le, Youssef Chelgoum, Aline Praire, Mauricette Michallet
Journal: Blood (2005)
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
Authors: Torben Plesner, Hendrik-Tobias Arkenau, Henk M. Lokhorst, Peter Gimsing, Jakub Krejcik, Charlotte Rose Lemech, Monique Minnema, Ulrik Niels Lassen, Tahamtan Ahmadi, Howard Yeh, Mary Guckert, Nikolai C. Brun, Steen Lisby, Linda Basse, Antonio Palumbo, Paul G. Richardson
Journal: Journal of Clinical Oncology (2014)

8533 Background: Daratumumab (DARA) (HuMax-CD38), a human IgG1κ monoclonal antibody effectively mediates destruction of CD38-expressing malignant plasma cells. In the first-in-human dose-escalation study, 42% of heavily pretreated patients with relapsed or relapsed, refractory (RR) multiple myeloma (MM) treated with DARA alone (≥4mg/kg) achieved partial response (PR) and 25% had minimal response (MR) (modified IMWG guidelines). In preclinical studies, DARA + lenalidomide (LEN) enhanced killing of MM cells in vitro.We evaluated safety, pharmacokinetics (PK) and efficacy of DARA + LEN + dexamethasone (DEX) in patients with relapsed or RR MM. Methods: In this ongoing phase I/II open-label multicenter dose-escalation (part 1) study, patients (≥ 18 years old) with life expectancy ≥3 months and ECOG status 0, 1 or 2 received DARA+LEN+DEX: (DARA [2-16 mg/kg] per week [8 wks], twice a month [16 wks], then, once monthly until disease progression, unmanageable toxicity or ≤24 months; LEN [25 mg]; DEX [40 mg] once weekly). Cohort expansion (part 2) study explores testing of maximum DARA dose determined in part 1. Results: Data from 12 patients (10 men, 2 women), median age 62 years (48-76) are evaluable to date. Median prior therapies: 4 (2-4); median ECOG status: 0.5 (0-1); median DARA infusions: 14.5 (1-23); median infusion time: 6.6 (5.9-7.3) hours. One patient (2 mg/kg dose) withdrew from study due to recurrent grade 1 QT prolongation and hypokalemia. Most frequent (>40% patients) adverse events were neutropenia and diarrhea; 17 were ≥ grade 3 with 70% hematological (neutropenia, thrombocytopenia, anemia). MTD was not reached. DARA+LEN+DEX PK-profile was similar to DARA alone suggesting LEN and DEX do not affect the DARA PK-profile. Available efficacy data from 11 patients demonstrated marked decrease in M-protein in all patients; 8/11 patients achieved PR or better, 5/11 with VGPR, 2/11 with MR. Median time to response was 4.1 weeks (2.1-4.3). Conclusions: DARA+LEN+DEX has favorable safety profile with manageable toxicities in relapsed and RR MM. Encouraging early activity is seen with marked reduction in M-protein and 8/11 patients (72%) achieving PR or better. Part 2 data will be presented. Clinical trial information: 2011-005709-62.
Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL)
Authors: Elias Jabbour, Susan O'Brien, Koji Sasaki, Deborah A Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Nitin Jain, Marina Konopleva, Jovitta Jacob, Rebecca Garris, Jorge E. Cortes, Hagop M. Kantarjian
Journal: Blood (2015)
Silvestrol Modulates Indirect Anti-Tumor Activity and Potentiates Immune Response To Epstein-Barr Virus-Driven Lymphoproliferative Disease
Authors: Alex S. Hartlage, Li Pan, Mark E Lustberg, Callie M. Drohan, Marisa F. Martin, A. Douglas Kinghorn, Michael A. Caligiuri, Michael R. Grever, David M. Lucas, Robert A. Baiocchi
Journal: Blood (2013)
The Prognostic Significance Of Interim PET/CT Using Visual, SUV-Based and MTV-Based Assessment In Treatment Of Peripheral T Cell Lymphoma
Authors: Deok-Hwan Yang, Jung-Joon Min, Jae-Sook Ahn, Yeo-Kyeoung Kim, Hee-Seung Bom, Hyeoung-Joon Kim, Yee Soo Chae, Sang Kyun Sohn, Sang Woo Lee, Young-Rok Do, Je-Jung Lee
Journal: Blood (2013)
Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis
Authors: M. Lievre, F. Gueyffier, T. Ekbom, R. Fagard, J. Cutler, E. Schron, M. Marre, J.-P. Boissel
Journal: Diabetes Care (2000)

OBJECTIVE- To review the effectiveness of diuretic or β-blocker-based treatment of hypertension in diabetic patients. RESEARCH DESIGN AND METHODS- A meta-analysis on individual patient data was performed on four trials of the treatment of hypertension in which diabetic patients were included and treated with first-line diuretics or β-blockers. The main outcomes were the relative risk of death, fatal or nonfatal stroke, fatal or nonfatal coronary events, and major cardiovascular events. RESULTS- There were 92 diabetic patients who received first-line β-blockers and 1.008 who received diuretics. In the control groups, diabetic patients had nearly twice the risk of any outcome when compared with nondiabetic patients. The same blood pressure reduction was achieved under treatment in the diabetic and nondiahetic patients, except for systolic pressure, which decreased more in the nondiabetic patients at 1 year. In the 15,843 nondiabetic patients, the risk of all four outcomes was reduced significantly in the treated group In the 2,254 diabetic patients, the risk reduction was significant only for fatal and nonfatal stroke (36%, P = 0.011) and major cardiovascular events (20%, P = 0.032), but not for death (5%, P = 0.65) and fatal or nonfatal coronary events (15%, P = 0.23). However, no heterogeneity was detected between diabetic patients and nondiabetic patients for any outcome. The numbers of outcomes avoided for 1,000 patients treated for 5 years were higher in diabetic patients (e.g. 38 major cardiovascular events) than with nondiahetic patients (e.g., 28 major cardiovascular events). CONCLUSIONS- These results show that hypertensive diabetic patients benefit from first-line treatment with diuretics. No conclusion can be drawn for β-blockers, owing to the small sample size.
An Evolving Approach to the Detection of Melanoma and Other Skin Cancers Using In Vivo Reflectance Confocal Microscopy
Authors: Alon Scope, Michael A. Marchetti
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Impact of emergency department care on outcomes of acute pain events in children with sickle cell disease
Authors: Amanda M. Brandow, Mark Nimmer, Timothy Simmons, T. Charles Casper, Lawrence J. Cook, Corrie E. Chumpitazi, J. Paul Scott, Julie A. Panepinto, David C. Brousseau
Journal: American Journal of Hematology (2016)

The impact of emergency department (ED) treatment on outcomes of sickle cell disease (SCD) acute pain hospitalizations is not well described. We investigated whether length of stay (LOS) and change in health-related quality of life (HRQL) are affected by initial opioid dose and time to administration. We conducted secondary analyses of data from the randomized-controlled Magnesium for children in Crisis (MAGiC) trial. The primary outcome was LOS. Secondary outcome was change in HRQL, assessed using PedsQL SCD Pain and Hurt and Pain Impact Domains measured in ED and at discharge. Independent variables were (1) time to first IV opioid, (2) total initial opioid dose (mg/kg/hr of morphine equivalents administered between ED and first study drug), and (3) Time to first oral opioid. Spearman correlations determined the associations with LOS. Using two-sample t-tests, we compared mean change in HRQL scores between IV opioid initiated within 60 and >60 min, opioid doses in the highest and lowest tertiles, and oral opioid initiated within 24 and >24 hr. Two hundred and four patients participated at 8 sites. Mean (SD) age was 13.6 (4.7) years. Earlier initiation of oral opioids was strongly correlated with shorter LOS (r = 0.61, P < 0.01). Higher initial opioid dose was weakly correlated with longer LOS (r = 0.34, P < 0.01). Higher initial opioid doses (6 vs -2.2; P = 0.01) and oral opioids initiated within 24 hr (5.7 vs -1.7, P = 0.04) were associated with larger mean change in HRQL at discharge. Prospective trials evaluating the impact of ED care on outcomes of pain hospitalizations could improve SCD pain treatment. Am. J. Hematol. 91:1175-1180, 2016. © 2016 Wiley Periodicals, Inc.
Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
Authors: Cara Ann Rosenbaum, Leonor Ano Stephens, Vishal Kukreti, Jeffrey A. Zonder, Craig Cole, Todd M. Zimmerman, Donna Ellen Reece, Jesus G. Berdeja, Erica Severson, Andrea Revethis, Brittany Wolfe, Kathryn McDonnell, Jennifer Nam, Kent A. Griffith, Andrzej J. Jakubowiak
Journal: Journal of Clinical Oncology (2016)

8007 Background: The combination of carfilzomib (CFZ), pomalidomide (POM) and dexamethasone (DEX) showed very promising activity in advanced RRMM. In this phase 1/2 study, KPd was evaluated in less-pretreated, primarily proteasome inhibitor (PI)-naïve/sensitive pt population. Methods: LEN-refractory disease was required for 2nd line, LEN-refractory/exposure for 3rd line or later. The phase 1 dose escalation to determine MTD followed the TITE-CRM algorithm with 40 pts receiving 3–4 mg POM PO (d1–21), 20–36 mg/m2CFZ (IV d1, 2, 8, 9, 15, 16 in C1–8, and d1, 2, 15, 16 in C9+), and 40/20 mg DEX PO weekly (C1–4/5–8; for all dose levels) in 28-day cycles. Per study design, 30 PI-naïve/sensitive pts were to be enrolled at the MTD across phases 1/2, with PR rate after 4 cycles as 1º efficacy end-point. Results: As of 1/29/16, a total of 55 pts have been enrolled with efficacy and safety data available on 44 pts, 4 at level (L) 1 (20 mg/m2 CFZ, 3 mg POM), 26 at L2 (20 mg/m2 CFZ, 4 mg POM), 14 at L3 (20/27 mg/m2 CFZ, 4 mg POM), none at L4 (20/36 mg/m2CFZ, 4 mg POM). Median age was 63, median time from diagnosis 7.1 yrs, median prior lines 2, refractory disease 75%, and high-risk disease per IMWG 28%. The MTD has been established at L3; there were 9 DLTs, all asymptomatic cytopenias, 8 G3 neutropenias and 1 G4 thrombocytopenia. G3/4 hematologic toxicities to date included 21% neutropenia and 7% thrombocytopenia and non-hematologic toxicities (all grades) were fatigue (60%), infection (56%), and GI (49%). Responses were rapid with 76% ≥PR after 1 cycle. After 4 cycles ≥PR was 77%; after a median of 7.2 cycles (0.6–27.1) ≥PR was 84%, ≥MR 91%, ≥VGPR 26%, and CR/nCR 12%. In the 1º population (N=35, 23 LEN-refractory, 10 progressing on LEN maintenance) ≥PR was 86% with 14 treated at MTD at the cut-off date. After a median f/u of 18 (1-39) mo, median PFS for all 55 pts enrolled was 12.9 mo and the estimated 18 mo OS was 86.5% with 32 remaining on treatment Conclusions: KPd is well tolerated and highly active (≥PR 84%) with encouraging PFS (median 12.9 mo) in less pretreated, mostly LEN-refractory and PI-naive/sensitive RRMM in the era of increased use of extended LEN treatment. Clinical trial information: NCT01665794.
ABCC1 confers tissue-specific sensitivity to cortisol versus corticosterone: A rationale for safer glucocorticoid replacement therapy
Authors: Mark Nixon, Scott D. Mackenzie, Ashley I. Taylor, Natalie Z. M. Homer, Dawn E. Livingstone, Rabah Mouras, Ruth A. Morgan, Damian J. Mole, Roland H. Stimson, Rebecca M. Reynolds, Alistair P. D. Elfick, Ruth Andrew, Brian R. Walker
Journal: Science Translational Medicine (2016)

Corticosterone is as effective as cortisol for ACTH suppression but lacks metabolic adverse effects.
Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings
Authors: Rui-Lan Huang, Po-Hsuan Su, Yu-Ping Liao, Tzu-I Wu, Ya-Ting Hsu, Wei-Yu Lin, Hui-Chen Wang, Yu-Chun Weng, Yu-Che Ou, Tim Hui-Ming Huang, Hung-Cheng Lai
Journal: Clinical Cancer Research (2016)

Endometrial cancer is a common gynecologic cancer whose incidence is increasing annually worldwide. Current methods to detect endometrial cancer are unreliable and biomarkers are unsatisfactory for screening. Cervical scrapings were reported as a potential source of material for molecular testing. DNA methylation is a promising cancer biomarker, but limited use for detecting endometrial cancer.We analyzed two methylomics databases of endometrioid-type endometrial cancer. Using nonnegative matrix factorization algorithm clustered the methylation pattern and reduced the candidate genes. We verified in pools DNA from endometrial cancer tissues and cervical scrapings, and validated in 146 cervical scrapings from patients with endometrioid-type endometrial cancer (n = 50), uterine myoma (n = 40), and healthy controls (n = 56) using quantitative methylation-specific PCR (QMSP). The logistic regression was used to evaluate the performance of methylation signal and gene combination.We filtered out 180 methylated genes, which constituted four consensus clusters. Serial testing of tissues and cervical scrapings detected 14 genes that are hypermethylated in endometrial cancer. Three genes, BHLHE22, CDO1, and CELF4, had the best performance. Individual genes were sensitivity of 83.7%-96.0% and specificity of 78.7%-96.0%. A panel comprising any two of the three hypermethylated genes reached a sensitivity of 91.8%, specificity of 95.5%, and odds ratio of 236.3 (95% confidence interval, 56.4-989.6). These markers were also applied to cervical scrapings of type II endometrial cancer patients, and detected in 13 of 14 patients.This study demonstrates the potential use of methylated BHLHE22/CDO1/CELF4 panel for endometrial cancer screening of cervical scrapings. Clin Cancer Res; 23(1); 263-72. ©2016 AACR.
The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism
Authors: Nienke Schotten, Pieternel C. M. Pasker-de Jong, Diego Moretti, Michael B. Zimmermann, Anneke J. Geurts-Moespot, Dorine W. Swinkels, Marian G. J. van Kraaij
Journal: Blood (2016)
Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™
Authors: Sam Schulman, Henry Eriksson, Samuel Z. Goldhaber, Ajay Kakkar, Clive Kearon, Sebastian M Schellong, Martin Feuring, Jeffrey Friedman, Joerg Kreuzer
Journal: Blood (2014)
394P A self-controlled trial of prophylactic topical application of vitamin K1 cream for cetuximab-related skin rash
Authors: H. Ishikawa, T. Kato, K. Yamazaki, K. Taku, T. Tsushima, Y. Yoshida, S. Hamauchi, S. Yoshikawa, H. Yagi, M. Kimura, M. Kimura, M. Nakajo, S. Sakata, H. Masujima, A. Miyazawa, M. Izawa, K. Iwami, T. Yamanaka, Y. Kiyohara
Journal: Annals of Oncology (2015)
Smoothened (SMO) Is an Adaptor Protein That Recruits TRAF6 and Phospholipase C Gamma 2 (PLCg2) to Enhance the Activation of NF-Kb Signaling Pathway
Authors: Nitin Agarwal, Chae Hwa Kim, Kranthi Kunkalla, Gloria Yang, Youley Tjendra, Yadong Liu, Changju Qu, Francisco Vega
Journal: Blood (2015)